Serious traders know that every second counts in these markets. Text messages are about 7x faster than email. Get an edge on other traders by receiving our FREE instant Stock Alerts ahead of e-mail subscribers by subscribing to our Mobile Alert System.
We promise never to share your number with anyone else. Standard text messaging rates may apply.
It’s not often that we come across a companies that could literally CHANGE THE WORLD in an immediate fashion.
But TODAY is one of those days.
With the COVID-19 Virus still raging across the globe, new strains emerging, and lockdowns still place, Today’s New Alert has never been more consequential.
WHY?
Because this stock is involved with what could be one of the Biggest BREAKTHROUGHS in COVID Testing to date!
And if that weren’t enough, this TRI-LISTED BioTech Stock in the US, Canada, and Germany, also has it’s hands in some of the most cutting-edge industries today from Cannabis, CBD, and even Psychedelics!
This, [fname], may be the GOLD-STANDARD in Low-Priced, Undervalued, Under-exposed stocks….
THIS….is XPHYF. And it must be put on your screen RIGHT NOW before Wall Street wakes up to it!!
XPhyto Therapeutics Corp. (XPHYF) is a Bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids.
A BREAKTHROUGH IN RAPID COVID TESTING
Most imminent of all is XPHYF’s exclusive Strategic Partnership with 3a-Diagnostics GmbH out in Germany.
XPHYF has a definitive development, technology purchase and license agreement with 3a, who is currently awaiting European Regulatory approval for what could be an absolute GAME-CHANGER in the fight against COVID-19.
Now most of us have likely gotten a COVID test over the last year.
By now we all know now that Rapid Tests are inaccurate and basically hit-or-miss and that the “Gold Standard” – the PCR Test (administered by a nasal swab) – can sometimes take over a week to provide results.
You see, the PCR test is based on genetics. It’s why other diagnostic testing methods, like antigen or serology (antibodies), do not provide the same level of accuracy as PCR.
PCR tests detect RNA – genetic material – that’s specific to the virus. The test is accurate enough to detect the virus within days of infection, even in people who have no symptoms.
So needless to say, all that time waiting for results could lead to the virus’s continued spread if that person does no responsibly quarantine.
So what if I told you that XPHYF and 3a could change ALL OF THAT?
Would you consider it a BREAKTHROUGH?REVOLUTIONARY?
A COVID PCR TEST IN JUST 25 MINUTES! XPHYF and 3a Diagonostics are developing a rapid, point-of-care, and easy-to-use infectious disease screening tests which include a COVID-19 (saliva-based) lateral flow assay and oral dissolvable biosensors for pandemic threats and dental health applications.
In other words, they have basically re-engineered the PCR diagnostic exam to make it what could be the world’s FASTEST and most portable Covid-19 test, with results delivered in as little as 25 minutes.
Best of all, XPHYF’s test is so portable it can be done with minimal equipment and training in a clinic, a hospital, a car – and what may turn out to be the most important settings – the test can be done at nursing homes, convalescent centers, airports, train stations, and office buildings.
And this is not just some “way out in the future” development….
XPHYF’s advance in Covid-19 testing could be ready to deploy immediately because European regulatory approval may be received any day now, as expected during 2021’s first quarter.
SO….with News that the breakthrough’s regulatory approval could happen soon, there’s little time to consider XPHYF – a direct beneficiary of this – BEFORE the Street rushes in!
IMPORTANT: While excitement about a 25-minute Covid-19 test seems justifiable, it’s equally important to clearly acknowledge this: that via its partner, 3a, what XPHYF has developed is in no way to be confused with a vaccine, cure, therapy, treatment, or containment strategy.
And now consider this…
The Global Rapid Test market is projected to reach USD $39.1 BIL by 2023 with a CAGR of 8.9% according to Allied Market Research.
So on one hand, XPHYF could very well change the world….but they can also seriously CAPITALIZE on it!
XYPHF’S PLAN FOR THE FUTURE
Upon European Regulatory approval, XPHYF plans to roll out it’s Rapid PCR Test across Europe at a very crucial time.
Currently, much of Europe and the United Kingdom are in lockdown, suffering from second and third waves of Covid-19 infections, including new strains that are even deadlier than the first.
To that end, XPHYF’s advanced testing platforms are ready for the future. Ready to tackle pandemic threats as they arise.
The U.S. Department of Defense reports that “we have a long path ahead,” with the pandemic continuing to spread through 2021.
And, in fact, the world may need a rapid test for COVID-19 for many years to come because scientists doubt it can ever be fully eradicated.
So if that’s the case and it becomes a chronic reality like the flu, then XPHYF’s test could have a long successful run in front of it.
XPHYF – A DIVERSE BIOSCIENCE PLAY
Now you didn’t think XPHYF just developed revolutionary COVID tests did you?
This is a company that has it’s hands in some of the HOTTEST industries today through it’s various subsidiaries and partners.
Among the most notable are it’s work in combating epilepsy using CBD with proprietary sublingual thin film technology through it’s subsidiary Vektor Pharma and challenging GW Pharma’s (NASDAQ: GWPH) dominance.
XPHYF aims to tackle chronic pain, infectious disease detection, appetite regulation, inflammatory dermatology, and sleep disorders through several novel drug delivery technologies, including sublingual (under the tongue) and transdermal (on the skin) thin films that are biodegradable..
THIS IS A MASSIVELY GROWING MARKET!
Analysis from Market Data Forecast reports that the global thin-film market will grow at 9% CAGR to reach $29.2 BIL by 2025, an increase of more than $10 BIL over today.
Most cutting edge of all is XPHYF’s bold foray into Psychedelics for usage in mental health and psychotherapy.
We’ll get to more of that as the week progresses….
THE BOTTOM LINE XPHYF is NOT a pipe dream!
The company could see European Regulatory Approval for it’s 25 MINUTE Rapid COVID PCR tests ANY DAY NOW and Wall Street is still BARELY aware of it!!
But the Street is starting to wake up to it…
XPHYF is still cheap under $3 but is on the move as we speak – trading in a strong Bullish Trend and nearing “Blue Skies Territory” with no upper chart resistance!
We’re also watching for a potentially IMMINENT “GOLDEN CROSS” of the 50 Day Moving Average through the 200 Day.
And lets not forget that Investing.com currently gives XPHYF it’s Top Rating of “STRONG BUY”!
Barchart.com currently rates this a “BUY” which just means we’ve got plenty of room to grow…
So with a healthy chart, a BREAKTHROUGH Rapid Test to combat COVID, and a suite of Cutting-Edge Biotech initiatives in CBD and Psychedelics, XPHYF must not be missed this week!
Make sure you put it on your screen RIGHT NOW and Follow on Twitter for all the Updates + Play-by-Play!
Good Trading,
Xavier Wright
Editor | WallStreetAlerts.org
Still need an Online Broker to place trades? RobinHood does NOT work!
Our Analysts HIGHLY recommend E*TRADE!
We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.
COMPENSATION: WallStreetAlerts.org has been compensated one-hundred and twenty thousand dollars cash via bank wire by XPhyto Therapeutics Corp. for a three day Xphyto Therapeutics Corp. marketing services contract. WallStreetAlerts.org does not own any shares of XPHYF. WallStreetAlerts.org does not investigate the background of any company or third party. The company or third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
